| Sanofi-Aventis (Suisse) SA - Mutagrip, suspension injectable | | 00373 | | 27 | | Mutagrip | | suspension injectable | | J07BB02 | | Influenza, gereinigtes Antigen | | 08.08.2018 | | |
| | Zusammensetzung | | haemagglutininum influenzae A (H1N1) (Virus souche A/Michigan/45/2015 (H1N1)-like: reassortant virus NYMC X-275) 15 µg, haemagglutininum influenzae A (H3N2) (Virus souche A/Singapore/INFIMH-16-0019/2016 (H3N2)-like: reassortant virus IVR-186) 15 µg, haemagglutininum influenzae B (Virus souche B/Colorado/06/2017-like: reassortant virus NYMC BX-69A derived from B/Maryland/15/2016) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, residui: formaldehydum max. 30 µg, octoxinolum-9 max. 200 µg, neomycinum max. 7.5 pg, ovalbuminum max. 50 ng, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml. | | Packungsbestandteile | | | | | | | | Wirkstoffe | Stärke |
|---|
| | 15 µg | | | 15 µg | | | 15 µg |
| | | | Hilfsstoffe | Stärke | Zusätzliche Information |
|---|
| Dinatrii Phosphas Dihydricus | | | | Formaldehydum | 30 µg | residui | | Kalii Chloridum | | | | Kalii Dihydrogenophosphas | | | | Natrii Chloridum | | | | Neomycinum | 7.5 | | | | 200 µg | | | | 50 ng | | | | | |
|
| | Packungsnummer | Packungsgrösse | EFP | PP | Kat. | SL | In Refdata nicht gelistet |
|---|
| Es wurden keine Einträge gefunden. |
|
|
